Sucampo Pharmaceuticals — Merger or Acquisition (April 2017)
15 slides from Sucampo Pharmaceuticals's merger presentation, Apr 3, 2017
Slide 1: Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases
Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements about the development and potential commercialization of VTS - 270, the timing of expected clinical trial resu
Slide 3: Non-GAAP Metrics
Non - GAAP Metrics This presentation contains four financial metrics (Adjusted Net Income, EBITDA, Adjusted EBITA and Free Cash Flow) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metr ics shou
Slide 4: Overview of Vtesse Inc. Acquisition
Overview of Vtesse Inc. Acquisition 4 • Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann - Pick Type C1, VTS - 270, for $200 million upfront consideration • No external financing required Overview • Builds on Sucampo’s capabilities, global development p
Slide 5: Transaction Overview
Transaction Overview • Sucampo to acquire Vtesse for a total upfront consideration of $200 million • Acquisition to be financed through the issuance of 2,782,678 Sucampo Class A common shares and $170 million in cash on hand, subject to customary adjustments; no external financing required • Conting
Slide 6: Vtesse: A Patient-Focused, Rare Disease Company
Vtesse: A Patient - Focused, Rare Disease Company • Privately - held company focused on developing drugs for patients suffering from devastating diseases • VTS - 270 for treatment of Niemann - Pick Disease Type C1 (NPC - 1) • Mechanism and intrathecal route of administration directly address most de
Slide 7: NPC-1: Ultra-Rare, Fatal Pediatric Disease with Urgent Patient Need
NPC - 1: Ultra - Rare, Fatal Pediatric Disease with Urgent Patient Need • NPC - 1 is an ultra - rare, progressive and fatal disease caused by defects in lipid transformation within the cell • Diagnosis of NPC - 1 most common outside infantile ages • Progressive and irreversible neurological manifest
Slide 8: NPC Overview, cont.
NPC - 1 Overview, cont. • NPC genes (NPC1 and NPC2) code for proteins that act sequentially to release cholesterol into cells • Mutations in either of these genes cause un - esterified cholesterol and other lipids to become sequestered and impair transport to plasma membrane and endoplasmic reticulu
Slide 9: Drug candidate for Treatment of NPC-1
VTS - 270 for Treatment of NPC - 1 • VTS - 270 is a highly - purified mixture of 2 - hydroxypropyl - ß - cyclodextrins with a specific compositional fingerprint that targets cholesterol and sphingolipid storage • Initially evaluated by consortium of academic labs led by NIH in collaboration with par
Slide 10: Clinical Data Phase 1/2 Study
Clinical Data Phase 1/2 Study 18 Month Treatment Results Reveal that VTS - 270 Shows Robust Disease Modification with Durable Effects Over 18 Months Disease Domain 18 - Month Results Natural History VTS - 270 Treated NPC Score * NPC Score with hearing removed * Ambulation * Fine Motor Cognition * Sw
Slide 11: Pivotal Trial
Until regulatory decision VTS - 270 Pivotal Trial • IT injections every 2 weeks • Trial fully enrolled • Pivotal data expected in mid - 2018 • Potential regulatory approval in U.S. and EU in 1H19 • Phase 1 patients currently in Part C on therapy >36 months Phase 3 Study Endpoints 1. Composite score
Slide 12: FDA & EMA Regulatory Status
FDA & EMA VTS - 270 Regulatory Status FDA MHRA FDA Orphan designation granted by US FDA and EMA Exclusivity post - approval: • 7 years in US • 10 years in Europe Breakthrough Therapy designation by US FDA UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted VTS - 270 a Promising I
Slide 13: Financial Impact
Financial Impact • Full Year 2017 Guidance Pre and Post Acquisition • Accretive to earnings beginning in 2019 Guidance ($’s M) except EPS Previous Full Year 2017 Guidance Pre Vtesse Revised Full Year 2017 Guidance Post Vtesse Revenue $220 – $ 230 $220 – $230 Adj. Net Income $80 – $90 $56 – $66 Adj.
Slide 14: Conclusion
Conclusion Aligns with Sucampo’s focus on patients and meeting the challenges of diseases with high unmet medical need Diversifies company and expands further in rare, orphan diseases and pediatric arena Sucampo brings global capabilities and resources to accelerate approval and commercialize VTS -
Slide 15: Q&A Session
Q&A Session
Sucampo Pharmaceuticals — Merger or Acquisition (April 2017) on 6ix